Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines. King LM, Lewnard JA. Vaccine 2024;42:126310.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

King LM, Lewnard JA. Health-economic burden attributable to novel serotypes in candidate 24- and 31-valent pneumococcal conjugate vaccines. Vaccine 2024;42:126310.
PMID: 39260055